Education
About Us
Working with TipRanks
Follow Us
Cibus (CBUS)
NASDAQ:CBUS
CBUS Stock Chart & Stats
$1.90
-$0.23(-7.99%)
At close: 4:00 PM EST
$1.90
-$0.23(-7.99%)
Day’s Range― - ―
52-Week Range$1.09 - $3.40
Previous CloseN/A
Volume64.89K
Average Volume (3M)154.04K
Market Cap
$103.14M
Enterprise Value$305.48M
Total Cash (Recent Filing)$23.89M
Total Debt (Recent Filing)$33.95M
Price to Earnings (P/E)―
Beta2.96
Next Earnings
Mar 19, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding52,707,626
10 Day Avg. Volume164,630
30 Day Avg. Volume154,044
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.70
Price to Sales (P/S)15.15
P/FCF Ratio-1.10
Enterprise Value/Market Cap2.96
Enterprise Value/Revenue80.52
Enterprise Value/Gross Profit127.28
Enterprise Value/Ebitda-3.57
Forecast
1Y Price Target
$18.67Price Target Upside882.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.39
Revenue Forecast (FY)$4.17M
Bulls Say, Bears Say
Bulls Say
EU Regulatory PathwayEU agreement on New Genomic Techniques establishes a clearer legal pathway that can speed development and market access for resilient, climate-adapted crop varieties.
Intellectual PropertyCreation of a patenting expert group for NGT plants could strengthen intellectual property protections and encourage competitive innovation around the company’s pipeline traits.
Product CommercializationCompletion of pre-commercial pilot fermentation runs for two biofragrance products positions the company to begin initial commercialization and diversify revenue beyond seed-trait offerings.
Bears Say
Financing RiskAnticipated need to raise additional capital in 2026 increases the risk of equity dilution and creates near-term financing pressure if major development partnerships are not secured.
Regulatory Burden For TraitsClassification of the company's herbicide tolerance traits as NGT-2 subjects them to authorization, traceability, and monitoring requirements similar to GMOs, which could slow adoption and raise compliance costs.
Cibus News
CBUS FAQ
What was Cibus’s price range in the past 12 months?
Cibus lowest stock price was $1.09 and its highest was $3.40 in the past 12 months.
What is Cibus’s market cap?
Cibus’s market cap is $103.14M.
When is Cibus’s upcoming earnings report date?
Cibus’s upcoming earnings report date is Mar 19, 2026 which is in 60 days.
How were Cibus’s earnings last quarter?
Cibus released its earnings results on Nov 13, 2025. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.438 by -$0.002.
Is Cibus overvalued?
According to Wall Street analysts Cibus’s price is currently Undervalued.
Does Cibus pay dividends?
Cibus does not currently pay dividends.
What is Cibus’s EPS estimate?
Cibus’s EPS estimate is -0.34.
How many shares outstanding does Cibus have?
Cibus has 52,707,626 shares outstanding.
What happened to Cibus’s price movement after its last earnings report?
Cibus reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.438. Following the earnings report the stock price went down -2.4%.
Which hedge fund is a major shareholder of Cibus?
Currently, no hedge funds are holding shares in CBUS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cibus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.67 (882.63% Upside)
$18.67 (882.63% Upside)
Hedge Fund Trend
Decreased
By 22.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.92%
12-Months-Change
Fundamentals
Return on Equity
-149.99%
Trailing 12-Months
Asset Growth
-10.23%
Trailing 12-Months
Company Description
Cibus
Cibus, Inc., a agricultural technology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The company is based in San Diego, California.
CBUS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in commercialization, particularly in rice herbicide tolerance traits and biofragrance products, alongside notable regulatory advances. However, challenges include a revenue decline and cash runway concerns, with some regulatory delays in the EU. Overall, the call reflects a cautiously optimistic outlook.View all CBUS earnings summariesCBUS Stock 12 Month Forecast
Average Price Target
$18.67
▲(882.63% Upside)
Technical Analysis
CervoMed
―
X4 Pharmaceuticals
―
ABVC BioPharma
―
Repare Therapeutics
―
OKYO Pharma Limited Sponsored ADR
―
Ownership Overview
32.55% Insiders
9.28% Mutual Funds
0.04% Other Institutional Investors
55.95% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---